Completed PHASE1 INTERVENTIONAL 1-arm NCT06035900

Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate (Psilocin-1)

Phase 1, Open-Label, One-Treatment, Single-Dose, One-Period, Pharmacokinetic Study of Psilocin 4 mg as Its Mucic Acid Salt (L-130) Form, in Healthy Subjects Under Fasted Conditions

Sponsor: Lobe Sciences Ltd.

Conditions Side Effect of Drug

Interventions Psilocin

Updated 3 times since 2023 Last updated: Sep 6, 2023 Started: Jun 21, 2023 Primary completion: Jul 30, 2023 Completion: Jul 30, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06035900, this PHASE1 trial focuses on Side Effect of Drug and remains completed. Sponsored by Lobe Sciences Ltd., it has been updated 3 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2023 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lobe Sciences Ltd.
Pharmaceutical Research Unit, Jordan

Data source: Lobe Sciences Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Amman, Jordan